Table 2.

Risk-assessment tools and clinical biomarkers associated with POD24

ComponentsRisk groupsSurvivalPOD24
FLIPI Age; stage; Hb; LDH; nodal sites Low: 0-1
Intermediate: 2-3
High: 4-5 
Low: 92%
Intermediate: 90%
High: 67% 
Low/Intermediate: 4%-6%
High: 7%-14% 
FLIPI2 B2M; diameter lymph node; BMI; age Low: 0
Intermediate: 1-2
High: 3-5 
Low: 91%
Intermediate: 69%
High: 51% 
 
PRIMA-PI B2M; BMI Low: B2M ≤ 3, no BMI
Intermediate: B2M ≤ 3 with BMI
High: B2M > 3 
Low: 69%
Intermediate: 55%
High: 37% 
Low: 5%
Intermediate: 7%
High: 12% 
FLEX Male sex; sum of lesion dimension; grade 3A; extranodal sites; ECOG; Hb; B2M; NK cell count; LDH Low: 0-2
High: 3-9 
Low: 86%
High: 68% 
Low: 5%
High: 8% 
m7-FLIPI FLIPI; ECOG; mutation status of 7 genes (ARID1A, CARD11, CREBBP, EP300, EZH2, FOXO1, MEF2BLow: <0.8
High: >0.8 
Low: 77%
High: 38% 
Low: 7%
High: 17% 
POD24-PI High-risk FLIPI; mutation status of 3 genes (EP300, EZH2, FOXO1Low: <0.71
High: >0.71 
Low: 77%
High: 50% 
Low: 4%
High: 14% 
ComponentsRisk groupsSurvivalPOD24
FLIPI Age; stage; Hb; LDH; nodal sites Low: 0-1
Intermediate: 2-3
High: 4-5 
Low: 92%
Intermediate: 90%
High: 67% 
Low/Intermediate: 4%-6%
High: 7%-14% 
FLIPI2 B2M; diameter lymph node; BMI; age Low: 0
Intermediate: 1-2
High: 3-5 
Low: 91%
Intermediate: 69%
High: 51% 
 
PRIMA-PI B2M; BMI Low: B2M ≤ 3, no BMI
Intermediate: B2M ≤ 3 with BMI
High: B2M > 3 
Low: 69%
Intermediate: 55%
High: 37% 
Low: 5%
Intermediate: 7%
High: 12% 
FLEX Male sex; sum of lesion dimension; grade 3A; extranodal sites; ECOG; Hb; B2M; NK cell count; LDH Low: 0-2
High: 3-9 
Low: 86%
High: 68% 
Low: 5%
High: 8% 
m7-FLIPI FLIPI; ECOG; mutation status of 7 genes (ARID1A, CARD11, CREBBP, EP300, EZH2, FOXO1, MEF2BLow: <0.8
High: >0.8 
Low: 77%
High: 38% 
Low: 7%
High: 17% 
POD24-PI High-risk FLIPI; mutation status of 3 genes (EP300, EZH2, FOXO1Low: <0.71
High: >0.71 
Low: 77%
High: 50% 
Low: 4%
High: 14% 

BMI, body mass index; Hb, hemoglobin.

or Create an Account

Close Modal
Close Modal